Previous | Next
680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731731a of 999
only about 32 or 33% survive at three years. In other
words, you have nearly a doubling of survival.
Now, this is with giving interferon every day for
a month and twice a week for eighteen months. It may be
they're giving too small doses, and it may be that they're
not giving it in the right -- they're not giving it in pulses
(spurts). It seems that sometimes giving of a drug in pulses,
instead of giving it daily or once or twice a week --
You mean, that's in pulses, spurts?
Yes, in spurts. But at any rate, interferon is
better than anything else that's known at present as a non-toxic
drug. This is relatively non-toxic and prevents viral
infections in patients. About one-half of cancer patients
die of viral infections who are being treated for cancer
with toxic drugs.
There are similar results that are not quite as
good, but fairly similar, with very toxic drugs, such as
methotrexate, in osteogenic carcinoma, but to have a drug
that doesn't make you ill is a tremendous -- well, actually
the results aren't as good as this. They're around 50%,
not quite as good as this, with toxic drugs after operation.
At any rate, it's a tremendous advantage to have
a non-toxic drug, something that's naturally occurring in
your body, that the body can be stimulated by. Viral diseases
have already been shown to be effectively treated by interferon.
So Strander's work is really what stimulated me
to be interested in interferon.
© 2006 Columbia University
Libraries | Oral History
Research Office | Rights and
Permissions | Help